Invasive fungal infections are another top concern, as outlined by the World Health Organization’s Fungal Priority Pathogens ...

Oral cefixime is a third-generation cephalosporin that has a similar antibacterial spectrum to ceftriaxone. Cefixime is ...

New IDWeek 2024 study reveals disparities in PrEP uptake across key U.S. populations. While overall PrEP usage has increased, ...

A new study presented at IDWeek 2024 reveals that race and socioeconomic vulnerabilities significantly impact vaccine uptake ...

Clesrovimab, formerly known as MK-1654, is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody.

ATI-1701 provides full protection against lethal tularemia in animal models after one yearCompany to provide update on tularemia vaccine ...

SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® ...

Paris, October 9, 2024. Sanofi advances its ambition to protect all infants from respiratory syncytial virus (RSV) disease with new Beyfortus (nirsevimab) data to be presented at the Infectious ...

Data to be presented at IDWeek 2024 include: Presentation Title: Oral Sulopenem/probenecid for Uncomplicated Urinary Tract Infections (uUTI): Results from the REASSURE Trial Poster #: 1107 Presenter: ...

The results, along with interim findings from the ongoing phase 3 trial (MK-1654-007) of clesrovimab, were presented during IDWeek 2024, held October 16-19 in Los Angeles, California. Results from ...